Rasagiline in the pharmacotherapy of Parkinson’s disease – a review

Bibliography

• ZHANG Z-X, ROMAN GC: Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology (1993) 12(4):195–208.
   PubMed Web of Science ®Google Scholar
• DE RIJK MC, TZOURIO C, BRETELER MMB et al.: Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. J. NeuroL Neurosurg Psychiatry (1997) 62(1):10–15.
   PubMed Web of Science ®Google Scholar
• CLOUGH CG, CHAUDHURI KR, SETHI KD: Fast facts - Parkinson's disease. Health Press Limited, Oxford (2003).
   Google Scholar
• RASCOL 0, PAYOUX P, ORY F, FERREIRA JJ, BREFEL-COURBON C, MONTASTRUC JL: Limitations of current Parkinson's disease therapy. Ann. NeuroL (2003) 53\(Suppl. 3):53–515.
   Google Scholar
• MARSDEN CD: Parkinson's disease. Lancet (1990) 335(8695):948–952.
   PubMed Web of Science ®Google Scholar
• OLANOW WC, SCHAPIRA AHV, RASCOL 0: Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. (2000) 23(Suppl.):S117–S126.
   Google Scholar
• RASCOL 0, GOETZ C, KOLLER W, POEWE W, SAMPAIO C: Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet (2002) 359(9317):1589–1598.
   PubMed Web of Science ®Google Scholar
• •This is a recent evidence-based medicine review of all available antiparkinsonian treatments.
   Google Scholar
• RIEDERER P, LACHENMAYER L, LAUX G: Clinical applications of MAO-inhibitors. Curr. Med. Chem. (2004) 11(15):2033–2043.
   PubMed Web of Science ®Google Scholar
• ABU-RAYA S, TABAKMAN R, BLAUGRUND E, TREMBOVLER V, LAZAROVICI P: Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischaemia in PC12 cells. Eur. j Pharmacol (2002) 434(3):109–116.
   PubMed Web of Science ®Google Scholar
• BAR AM 0, AMIT T, YOUDIM MBH: Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. (2004) 355(3):169–172.
   PubMed Web of Science ®Google Scholar
• SIMPSON LL: Evidence that deprenyl, a type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem. Pharmacol (1978) 27(10:1591–1595.
   PubMed Web of Science ®Google Scholar
• GLEZER S, FINBERG JPM: Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur. j Pharmacol (2003) 472(3):173–177.
   PubMed Web of Science ®Google Scholar
• FINBERG JPM, LAMENSDORF I, WEINSTOCK M, SCHWARTZ M, YOUDIM MBH: Pharmacology of rasagiline (N-propargy1-1R-aminoindan). Adv. NeuroL (1999) 80:495–499.
   PubMedGoogle Scholar
• FINBERG JPM, SABBAGH A, YOUDIM MBH: Pharmacology of selective propargyl suicide inhibitors of monoamine oxidase. In: Enzymes and neurotransmitters in mental disease. Usdin E, Sourkes TL, Youdim MBH (Eds), John Wiley 8c Sons Ltd, Chichester (1980):207–219.
   Google Scholar
• LEES AJ: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's disease Research Group of the United Kingdom. Br. Med. J. (1995) 311(7020):1602–1607.
   PubMed Web of Science ®Google Scholar
• STERLING J, VEINBERG A, LERNER D et al.: (R)(+)-N-propargy1-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J. Neural Transm. (1998) 52(Suppl.):301–305.
   Google Scholar
• CLARKE A. BREWER F, JOHNSON ES et al.: A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J. Neural Transm. (2003) 110(11):1241–1255.
   Google Scholar
• THÉBAULT JJ, GUILLAUME M, LEVY R: Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy (2004) 24(10):1295–1305.
   PubMed Web of Science ®Google Scholar
• •This study summarises the main pharmacological properties of rasagiline in healthy volunteers.
   Google Scholar
• TEVA PHARMACEUTICAL INDUSTRIES LTD: Azilect® (rasagiline mesylate tablets) summary of product characteristics. Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel.
   Google Scholar
• YOUDIM MBH, GROSS A, FINBERG JPM: Rasagiline 1N-propargy1-1R(+)-aminoindanl, a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol (2001) 132(2):500–506.
   PubMed Web of Science ®Google Scholar
• FOLEY P, GERLACH M, YOUDIM MBH, RIEDERER P: MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat. Disord. (2000) 6(1):25–47.
   Google Scholar
• LAMENSDORF I, YOUDIM MBH, FINBERG JPM: Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem. (1996) 67(4):1532–1539.
   PubMed Web of Science ®Google Scholar
• GOTZ ME, BREITHAUPT W, SAUTTER J et al.: Chronic TVP-1012 (rasagiline) dose - activity response of monoamine oxidases A and B in the brain of the common marmoset. J. Neural liyinsm. (1998) 52(Suppl.):271–278.
   Google Scholar
• FINBERG JPM, YOUDIM MBH: Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br. J. Pharmacol (1985) 85(2):541–546.
   PubMed Web of Science ®Google Scholar
• ABASSI ZA, BINAH 0, YOUDIM MBH: Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br. J. Pharmacology (2004) 143(3):371–378.
   PubMed Web of Science ®Google Scholar
• FINBERG JPM, WANG J, GOLDSTEIN DS, KOPIN IJ, BANKIEWICZ KS: Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J. Neurochem. (1995) 65(3):1213–1220.
   PubMed Web of Science ®Google Scholar
• FINBERG JPM, YOUDIM MBH: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology (2002) 43(7):1110–1118.
   PubMed Web of Science ®Google Scholar
• ARNETT CD, FOWLER JS, MACGREGOR RR et al.: Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-["C]deprenyl. j Neurochem. (1987) 49(2):522–527.
   PubMed Web of Science ®Google Scholar
• FOWLER JS, VOLKOW ND, LOGAN J et al.: Slow recovery of human brain MAO B after L-deprenyl (selegiline) withdrawal. Synapse (1994) 18(2):86–93.
   PubMed Web of Science ®Google Scholar
• RIEDERER P, YOUDIM MBH: Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl. J. Neurochem. (1986) 46(5):1359–1365.
   PubMed Web of Science ®Google Scholar
• FINBERG JPM, WANG J, BANKIEWICZ K, HARVEY-WHITE J, KOPIN IJ, GOLDSTEIN DS: Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J. Neural Transm. (1998) 52(Suppl.):279–285.
   Google Scholar
• WETHERELL JR, FOSBRAEY P, FRENCH MC: A comparison of the distribution of neurotransmitters in brain regions of the rat and guinea-pig using a chemiluminescent method and HPLC with electrochemical detection./ Neurochem. (1989) 53(5):1519–1526.
   PubMed Web of Science ®Google Scholar
• MOSES D, GROSS A, FINBERG JPM: Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig. Neuropharmacology (2004) 47(1):72–80.
   PubMed Web of Science ®Google Scholar
• •This study reports the symptomatic antiparkinsonian effect of rasagiline in vivo in an animal model of parkinsonism.
   Google Scholar
• SPEISER Z, LEVY R, COHEN S: Effects of N-propargy1-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders./ Neural Transm. (1998) 52(Suppl.):287–300.
   Google Scholar
• SPEISER Z, KATZIR 0, REHAVI M, ZABARSKI T, COHEN S: Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmaco. Biochem. Behav. (1998) 60(2):387–393.
   PubMed Web of Science ®Google Scholar
• AMINOFF MJ: Neuroprotective treatment for Parkinson's disease. Expert Rev. Neurother. (2003) 3(6):797–804.
   PubMedGoogle Scholar
• SCHAPIRA AHV, OLANOW CW: Neuroprotection in Parkinson's disease. JAMA (2004) 291(3):358–364.
   PubMed Web of Science ®Google Scholar
• •This is a recent review on neuroprotection in PD.
   Google Scholar
• YOUDIM MBH: Rasagiline: an antiParkinson drug with neuroprotective activity. Expert Rev. Neurother. (2003) 3(6):737–749.
   PubMedGoogle Scholar
• MARUYAMA W, YAMAMOTO T, KITANI K, CARRILLO MC, YOUDIM M, NAOI M: Mechanism underlying antiapoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. (2000) 116(2-3):181–191.
   PubMed Web of Science ®Google Scholar
• YOUDIM MBH, WEINSTOCK M: Novel neuroprotective antiAlzheimer drugs with antidepressant activity derived from the antiParkinson drug, rasagiline. Mech. Ageing Dev. (2002) 123(8):1081–1086.
   PubMed Web of Science ®Google Scholar
• MARUYAMA W, AKAO Y, CARRILLO MC, KITANI K, YOUDIM MBH, NAOI M: Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and inducation of prosurvival genes. Neurotoxicol Teratol. (2002) 24(5):675–682.
   PubMed Web of Science ®Google Scholar
• MANDEL S, GRONBLATT E, RIEDERER P, GERLACH M, LEVITES Y, YOUDIM MBH: Neuroprotective strategies in Parkinson's disease. An update on progress. CNS Drugs (2003) 17(10):729–762.
   PubMed Web of Science ®Google Scholar
• YOUDIM MBH, WADIA A, TATTON W, WEINSTOCK M: The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell cultures and in vivo. Ann. N 17.- Acad. Sci. (2001) 939:450–458.
   Google Scholar
• YOUDIM MBH, AMIT T, FALACH-YOGEV M, BAR AM 0, MARUYAMAW, NAOI M: The essentiality of Bc1-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the antiParkinson drug, rasagiline. Biochem. Pharmacol. (2003) 66(8):1635–1641.
   PubMed Web of Science ®Google Scholar
• GOGGI J, THEOFILOPOULOS S, RIAZ SS, JAUNIAUX E, STERN GM, BRADFORD HF: The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurons in culture. NeuroReport (2000) 11(18):3937–3941.
   PubMed Web of Science ®Google Scholar
• YOGEV-FALACH M, AMIT T, BAR-AM 0, YOUDIM MBH: The importance of propargylamine moiety in the antiParkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB (2003) 17(15):2325–2327.
   PubMed Web of Science ®Google Scholar
• WAIBEL S, REUTER A, MALESSA S, BLAUGRUND E, LUDOLPH AC: Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J. NeuroL (2004) 251(9):1080–1084.
   PubMed Web of Science ®Google Scholar
• BENCH CJ, PRICE GW, LAMMERTSMA AA et al.: Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur. J. Clin. Pharmacol (1991) 40(2):169–173.
   PubMed Web of Science ®Google Scholar
• KUPSCH A: Rasagiline. Teva Pharmaceutical. Curr. Opin. Investig Drugs (2002) 3(5):794–797.
   Google Scholar
• HEIKKILA RE, DUVOISIN RC, FINBERG JPM, YOUDIM MBH: Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. (1985) 116(3):313–317.
   PubMed Web of Science ®Google Scholar
• FINBERG JPM, LAMENSDORF I, COMMISSIONG JW, YOUDIM MBH: Pharmacology and neuroprotective properties of rasagiline. J. Neural Transm. (1996) 48(Suppl.):95–101.
   Google Scholar
• FREEDMAN N, MISHANI E, KRAUSZ Y, BLAUGRUND E, EHRLICH D, CHISIN R: In vivo measurement of brain monoamine oxidase (MAO-B) activity after rasagiline treatment using L- [1and positron emission tomography (PET). Mov. Disord. (2005) 20\(Suppl. 10):589.
   Google Scholar
• PARKINSON STUDY GROUP: A controlled trial of rasagiline in early Parkinson's disease. The TEMPO study. Arch. Neurol (2002) 59(12):1937–1943.
   PubMed Web of Science ®Google Scholar
• ••This study documents the symptomaticantiparkinsonian effect of rasagiline as monotherapy in patients with early PD.
   Google Scholar
• PARKINSON STUDY GROUP: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations. The PRESTO study. Arch. NeuroL (2005) 62(2):241–248.
   PubMed Web of Science ®Google Scholar
• •This is a large, placebo-controlled study showing the efficacy of rasagiline in the advanced stages of PD when adjunct to levodopa.
   Google Scholar
• RASCOL 0, BROOKS DJ, MELAMED E et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet (2005) 365:947–954.
   Google Scholar
• ••This is the sole large, randomised,controlled trial of rasagiline that incorporates an active comparator arm (entacapone) in its design. Although direct head-to-head comparison between rasagiline and entacapone was not performed, the study shows that both drugs have comparable efficacy (on the OFF episodes and UPDRS scores) and safety profiles.
   Google Scholar
• STERN MB, MAREK KL, FRIEDMAN J et al.: Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov. Disord. (2004) 19(8):916–923.
   PubMed Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch. Neurol (2004) 61(4):561–566.
   PubMed Web of Science ®Google Scholar
• ••This study provides preliminary clinicaldata supporting the putative impact of rasagiline on disease progression.
   Google Scholar
• RABEY JM, SAGI I, HUBERMAN E et al.: Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol (2000) 23(0:324–330.
   PubMed Web of Science ®Google Scholar
• SALZMAN PM, EYAL E, KUNKEL TJ, MALONE NT: Rasagiline provides significant benefit as initial monotherapy and as adjunct therapy in early and moderate-to-advanced Parkinson's disease (PD). Ann. Neurol. (2004) 56\(Suppl. 8):513.
   Google Scholar
• MAGYAR K, SZENDE B: (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and antiapoptotic properties. Neurotoxicology (2004) 25(1-2):233–242.
   PubMed Web of Science ®Google Scholar
• MANN JJ, AARONS SF, WILNER PJ et al.: A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch. Gen. Psychiatry (1989) 46(1):45–50.
   PubMed Web of Science ®Google Scholar
• MCGRATH PJ, STEWART JW, HARRISON W, WAGERS, NUNES EN, QUITKIN FM: A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull. (1989) 25(1):63–67.
   PubMed Web of Science ®Google Scholar
• BODKIN JA, AMSTERDAM JD: Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in out-patients. Am. J. Psychiatry (2002) 159(11):1869–1875.
   PubMed Web of Science ®Google Scholar
• RASCOL 0: Monoamine oxidase inhibitors - is it time to up the TEMPO? Lancet (2003) 2:142–143.
   Google Scholar
• CHURCHYARD A, MATHIAS CJ, BOONKONGCHUEN P, LEES AJ: Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J. Neurol Neurosurg-. Psychiatry (1997) 63(2):228–234.
   PubMed Web of Science ®Google Scholar
• CHURCHYARD A, MA ancITHIAS CJ, LEES AJ: Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Mov. Disord. (1999) 14(2):246–251.
   PubMed Web of Science ®Google Scholar
• BEN-SHLOMO Y, CHURCHYARD A, HEAD J et al.: Investigation by Parkinson's disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. Br. Med. J. (1998) 316(7139):1191–1196.
   PubMed Web of Science ®Google Scholar
• MOLLER H, MELLEMKJAER L, MCLAUGHLIN JK, OLSEN JH: Occurrence of different cancers in patients with Parkinson's disease. Br. Med. J. (1995) 310(6993):1500–1501.
   PubMed Web of Science ®Google Scholar
• OLSEN JH, FRITS S, FREDERIKSEN K, MCLAUGHLIN JK, MELLEMKJAER L, MOLLER H: Atypical cancer pattern in patients with Parkinson's disease. Br. J. Cancer (2005) 92(1):201–205.
   PubMed Web of Science ®Google Scholar